JP2018537975A5 - - Google Patents

Download PDF

Info

Publication number
JP2018537975A5
JP2018537975A5 JP2018527739A JP2018527739A JP2018537975A5 JP 2018537975 A5 JP2018537975 A5 JP 2018537975A5 JP 2018527739 A JP2018527739 A JP 2018527739A JP 2018527739 A JP2018527739 A JP 2018527739A JP 2018537975 A5 JP2018537975 A5 JP 2018537975A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
heavy chain
light chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018527739A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018537975A (ja
JP6979950B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2016/057017 external-priority patent/WO2017093844A1/en
Publication of JP2018537975A publication Critical patent/JP2018537975A/ja
Publication of JP2018537975A5 publication Critical patent/JP2018537975A5/ja
Application granted granted Critical
Publication of JP6979950B2 publication Critical patent/JP6979950B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018527739A 2015-11-30 2016-11-22 部位特異的ｈｅｒ２抗体薬物コンジュゲート Expired - Fee Related JP6979950B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201562260854P 2015-11-30 2015-11-30
US62/260,854 2015-11-30
US201662289744P 2016-02-01 2016-02-01
US201662289727P 2016-02-01 2016-02-01
US62/289,744 2016-02-01
US62/289,727 2016-02-01
US201662409105P 2016-10-17 2016-10-17
US62/409,105 2016-10-17
PCT/IB2016/057017 WO2017093844A1 (en) 2015-11-30 2016-11-22 Site specific her2 antibody drug conjugates

Publications (3)

Publication Number Publication Date
JP2018537975A JP2018537975A (ja) 2018-12-27
JP2018537975A5 true JP2018537975A5 (https=) 2020-01-16
JP6979950B2 JP6979950B2 (ja) 2021-12-15

Family

ID=57485830

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018527739A Expired - Fee Related JP6979950B2 (ja) 2015-11-30 2016-11-22 部位特異的ｈｅｒ２抗体薬物コンジュゲート

Country Status (17)

Country Link
US (2) US10689458B2 (https=)
EP (1) EP3383918A1 (https=)
JP (1) JP6979950B2 (https=)
KR (2) KR102312149B1 (https=)
CN (1) CN108473591B (https=)
AU (1) AU2016363373A1 (https=)
BR (1) BR112018010102A2 (https=)
CA (1) CA2949032A1 (https=)
CO (1) CO2018005433A2 (https=)
IL (1) IL259651B2 (https=)
MX (1) MX2018006582A (https=)
PH (1) PH12018501043A1 (https=)
RU (1) RU2745565C2 (https=)
SG (2) SG11201803676PA (https=)
TW (3) TWI727380B (https=)
WO (1) WO2017093844A1 (https=)
ZA (1) ZA201803205B (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015502397A (ja) 2011-12-23 2015-01-22 ファイザー・インク 部位特異的コンジュゲーションのための操作された抗体定常領域、ならびにそのための方法および使用
ES3007557T3 (en) * 2016-10-17 2025-03-20 Pfizer Anti-edb antibodies and antibody-drug conjugates
NZ762376A (en) 2017-09-19 2022-08-26 Scherrer Inst Paul Transglutaminase conjugation method and linker
US11364303B2 (en) 2017-09-29 2022-06-21 Pfizer Inc. Cysteine engineered antibody drug conjugates
CN119405832A (zh) 2018-06-01 2025-02-11 卫材R&D管理有限公司 剪接调节抗体-药物缀合物及其使用方法
US20220370606A1 (en) 2018-12-21 2022-11-24 Pfizer Inc. Combination Treatments Of Cancer Comprising A TLR Agonist
CN114901308A (zh) * 2019-10-29 2022-08-12 石药集团巨石生物制药有限公司 使用抗her2抗体药物缀合物治疗癌症的组合物和方法
BR112022011848A2 (pt) 2019-12-20 2022-11-22 Pfizer Tratamento com conjugados de anticorpo-fármaco her2 específicos de sítio
WO2021143741A1 (zh) * 2020-01-15 2021-07-22 北京海步医药科技有限公司 靶向多肽-药物缀合物及其用途
WO2022029591A1 (en) 2020-08-04 2022-02-10 Pfizer Inc. Treatment with site specific her2 antibody-drug conjugates
CN112202628B (zh) * 2020-09-08 2022-09-02 杭州涂鸦信息技术有限公司 一种WiFi模块串口协议自动化测试系统及方法
CN112285361B (zh) * 2020-09-27 2023-12-05 中国人民解放军空军军医大学 排除抗-cd38单克隆抗体药物对抗人球蛋白检测干扰的试剂
KR20230096052A (ko) 2020-10-25 2023-06-29 아라리스 바이오테크 아게 항체-링커 접합체를 생성하기 위한 수단 및 방법
WO2022174775A1 (en) * 2021-02-18 2022-08-25 Remegen Co., Ltd. Use of antibody-drug conjugate targeting her2 in treatment of specific breast cancer
KR20240074772A (ko) * 2021-10-10 2024-05-28 엘릭시론 이뮤노테라퓨틱스 (홍콩) 리미티드 항-pd-l1/il-10 융합 단백질을 이용한 질병 치료 방법
WO2023072934A1 (en) * 2021-10-25 2023-05-04 Araris Biotech Ag Methods for producing antibody-linker conjugates
EP4469485A4 (en) * 2022-01-26 2026-04-08 Biocytogen Pharmaceuticals Beijing Co Ltd ANTI-HER2/TROP2 ANTIBODIES AND THEIR USES
WO2024162772A1 (ko) * 2023-02-01 2024-08-08 주식회사 에이티지씨 생체 내 지속성이 증가된 생리활성물질의 결합체
WO2026025013A2 (en) 2024-07-26 2026-01-29 Pfizer Inc. Combination therapy using cdk4 inhibitors for cancer treatments
CN120738196B (zh) * 2025-09-03 2025-12-16 浙江博锐生物制药有限公司 编码抗her2抗体的核酸分子及其应用

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
GB9116610D0 (en) 1991-08-01 1991-09-18 Danbiosyst Uk Preparation of microparticles
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
WO2000053211A2 (en) 1999-03-09 2000-09-14 University Of Southern California Method of promoting myocyte proliferation and myocardial tissue repair
US6309633B1 (en) 1999-06-19 2001-10-30 Nobex Corporation Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
WO2001062299A2 (en) 2000-02-28 2001-08-30 Shearwater Corporation Water-soluble polymer conjugates of artelinic acid
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
EP2478912B1 (en) 2003-11-06 2016-08-31 Seattle Genetics, Inc. Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy
NZ579482A (en) 2004-06-01 2011-02-25 Genentech Inc Antibody drug conjugates and methods
DK1771482T3 (da) 2004-07-22 2014-10-20 Genentech Inc HER2-antistofsammensætning
DK1791565T3 (en) 2004-09-23 2016-08-01 Genentech Inc Cysteingensplejsede antibodies and conjugates
EP1853294A4 (en) 2005-03-03 2010-01-27 Covx Technologies Ireland Ltd ANTIANGIOGENIC COMPOUNDS
EP2354163A3 (en) 2005-09-26 2013-04-24 Medarex, Inc. Conjugates of duocarmycin and anti-CD70 or anti-PSMA antibodies
WO2008032833A1 (en) 2006-09-14 2008-03-20 Medical & Biological Laboratories Co., Ltd. Antibody having enhanced adcc activity and method for production thereof
US20090098115A1 (en) * 2006-10-20 2009-04-16 Lisa Michele Crocker Cell lines and animal models of HER2 expressing tumors
NZ584514A (en) 2007-10-19 2012-07-27 Genentech Inc Cysteine engineered anti-tenb2 antibodies and antibody drug conjugates
BRPI0907046A2 (pt) 2008-01-18 2015-07-28 Medimmune Llc Anticorpo de cisteína engenheirada, ácido nucleico isolado, vetor, célula hospedeira, conjugado de anticorpo, composição farmacêutica, métodos de detecção de câncer, doenças ou distúrbios autoimunes, inflamatórios ou infecciosos em um indivíduo e de inibição de proliferação de uma célula alvo
KR101607346B1 (ko) 2008-01-31 2016-03-29 제넨테크, 인크. 항-ｃｄ７９ｂ 항체 및 면역접합체 및 사용 방법
EP2711018A1 (en) 2009-06-22 2014-03-26 MedImmune, LLC Engineered Fc regions for site-specific conjugation
CA2799540A1 (en) 2010-06-08 2011-12-15 Genentech, Inc. Cysteine engineered antibodies and conjugates
AU2011290672B2 (en) 2010-08-20 2015-07-09 Novartis Ag Antibodies for epidermal growth factor receptor 3 (HER3)
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
CA2813411C (en) 2010-11-05 2016-08-02 Rinat Neuroscience Corporation Engineered polypeptide conjugates and methods for making thereof using transglutaminase
US10208129B2 (en) 2010-12-06 2019-02-19 National Research Council Of Canada Antibodies selective for cells presenting ErbB2 at high density
US8852599B2 (en) 2011-05-26 2014-10-07 Bristol-Myers Squibb Company Immunoconjugates, compositions for making them, and methods of making and use
TWI495644B (zh) 2011-11-11 2015-08-11 Rinat Neuroscience Corp 營養層細胞表面抗原（Ｔｒｏｐ－２）之專一性抗體類及彼等之用途
CN104185477B (zh) * 2011-11-17 2017-05-24 辉瑞公司 细胞毒性肽及其抗体‑药物缀合物
JP2015502397A (ja) 2011-12-23 2015-01-22 ファイザー・インク 部位特異的コンジュゲーションのための操作された抗体定常領域、ならびにそのための方法および使用
US10011660B2 (en) 2012-04-30 2018-07-03 Medimmune, Llc Molecules with reduced effector function and extended half-lives, compositions, and uses thereof
WO2013173337A2 (en) 2012-05-15 2013-11-21 Seattle Genetics, Inc. Self-stabilizing linker conjugates
JP2015524821A (ja) 2012-08-02 2015-08-27 ジェイエヌ バイオサイエンシーズ エルエルシー システイン変異及びμ尾部を介して多量体化した抗体又は融合タンパク質
WO2014022846A1 (en) 2012-08-03 2014-02-06 Board Of Regents Of The University Of Nebraska Cancer biomarkers and methods of use thereof
SI2906252T1 (sl) 2012-10-12 2017-10-30 Adc Therapeutics Sa Pirolobenzodiazepin-anti-HER2 protitelesni konjugati
HRP20190366T1 (hr) 2012-10-12 2019-04-19 Medimmune Limited Pirolobenzodiazepini i njihovi konjugati
KR101763499B1 (ko) 2012-11-07 2017-07-31 화이자 인코포레이티드 항-il-13 수용체 알파 2 항체 및 항체-약물 접합체
EP2953976B1 (en) * 2013-02-08 2021-03-24 Novartis Ag Specific sites for modifying antibodies to make immunoconjugates
TWI680766B (zh) 2013-03-13 2020-01-01 英商梅迪繆思有限公司 吡咯并苯并二氮呯及其共軛物
EP3018143B1 (en) 2013-07-03 2019-05-29 Seoul National University R&DB Foundation Chicken antibody transformed into cysteine and site-specific conjugation using same
BR112016002829A2 (pt) 2013-08-12 2017-09-19 Genentech Inc Composto e processo para preparar o composto de conjugado anticorpo-¿droga, composição farmacêutica, método de tratamento do câncer, kit para o tratamento do câncer, intermediário ligante¿-droga, porção e composto de porção droga de dímero cbi
WO2015038426A1 (en) 2013-09-13 2015-03-19 Asana Biosciences, Llc Self-immolative linkers containing mandelic acid derivatives, drug-ligand conjugates for targeted therapies and uses thereof
US9239324B2 (en) 2013-12-06 2016-01-19 Gang Chen Antibody-binding protein-drug conjugate and methods of use
RU2698697C2 (ru) 2013-12-23 2019-08-29 Байер Фарма Акциенгезельшафт Конъюгаты связующего (ADC) с ингибиторами KSP
SG11201605437YA (en) 2014-01-27 2016-08-30 Pfizer Bifunctional cytotoxic agents
WO2015130173A1 (en) * 2014-02-28 2015-09-03 Merus B.V. Antibody that binds erbb-2 and erbb-3
SG11201608192SA (en) 2014-04-11 2016-10-28 Medimmune Llc Bispecific her2 antibodies
KR102486180B1 (ko) * 2014-06-06 2023-01-11 레드우드 바이오사이언스 인코포레이티드 항-her2 항체-메이탄신 컨쥬게이트 및 이것의 사용 방법
US10870706B2 (en) 2015-03-20 2020-12-22 Pfizer Inc. Bifunctional cytotoxic agents containing the CTI pharmacophore
TWI812873B (zh) 2015-11-30 2023-08-21 美商輝瑞股份有限公司 用於部位專一性接合之抗體和抗體片段

Similar Documents

Publication Publication Date Title
JP2018537975A5 (https=)
RU2018119683A (ru) Сайт-специфические конъюгаты антитела к her2 и лекарственного средства
TWI865337B (zh) 抗體-藥物結合物之有效的製造方法
US12497465B2 (en) Combination of antibody-drug conjugate and tubulin inhibitor
TWI722422B (zh) 抗體-藥物結合物
AU2015205588B2 (en) Duocarmycin ADCs for use in treatment of endometrial cancer
JP2019532056A5 (https=)
JP2015534577A5 (https=)
JP2016502504A5 (https=)
FI3283521T3 (fi) Lääkekonjugaatteja käsittäen vasta-aineita claudiinia 18.2 vastaan
JP2017514905A5 (https=)
JP2021519076A5 (https=)
ME02919B (me) Konjugati humanog antitijela sa lijekom protiv tkivnog faktora
JP2016505513A5 (https=)
JP2012522512A5 (https=)
JP2016528251A5 (https=)
JP2023545096A5 (https=)
CN106999606A (zh) 抗体药物偶联物
JP2016540826A5 (https=)
TW202525806A (zh) 基於分子膠降解劑之抗體-藥物結合物及其用途
TWI915810B (zh) 抗體-藥物結合物之改良製造方法
JP2025540063A (ja) 抗体－薬物コンジュゲートおよびｄｎｍｔ阻害剤の併用
BR122024023393A2 (pt) Uso de um conjugado de anticorpo-fármaco, composição farmacêutica, e, combinação farmacêutica
HK40130006A (zh) 通过施用抗her2抗体-药物缀合物治疗her2突变的癌
BR122024023391A2 (pt) Uso de um conjugado de anticorpo-fármaco, composição farmacêutica, e, combinação farmacêutica